Genentech's Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions | Business
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct 11, 2023--
Source: valdostadailytimes.com